Fidelity Investments’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Fidelity Investments’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-118,947	Closed	-$6.01M	–	4461
2020 Q3	$6.01M	Hold	118,947	–	–	﹤0.01%	2006
2020 Q2	$5.67M	Sell	118,947 -283,800	-70%	-$13.2M	﹤0.01%	2011
2020 Q1	$19.7M	Sell	402,747 -8,500	-2%	-$433K	﹤0.01%	1404
2019 Q4	$23.6M	Buy	411,247 +40,000	+11%	+$1.98M	﹤0.01%	1533
2019 Q3	$13.4M	Buy	371,247 +206,410	+125%	+$8.06M	﹤0.01%	1728
2019 Q2	$5.12M	Buy	+164,837	New	+$4.47M	﹤0.01%	2081

Other funds holding EIDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity Investments's EIDX Position: Q4 2020 in Review

Fidelity Investments sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 118,947 shares — an estimated $6.01M sold.

Fidelity Investments first reported a position in EIDX in Q2 2019 and held it in 6 quarters. The position peaked at $23.6M in Q4 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

Fidelity Investments reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Fidelity Investments sold 118,947 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $6.01M.
Fidelity Investments first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Fidelity Investments's Eidos Therapeutics, Inc. Common Stock position peaked at $23.6M in Q4 2019.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Fidelity Investments's 13F filing for Q4 2020, filed 8 Feb 2021.